Centene Corporation: Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Centene Corporation is a leading healthcare enterprise providing managed care services primarily through government-sponsored programs (Medicaid, Medicare) and commercial markets. The company operates in four segments: Medicaid, Medicare, Commercial, and Other. As of June 30, 2026, total managed care membership stood at 25.9 million, a decrease of 2.1 million (8%) year-over-year, driven by eligibility redeterminations in Medicaid and regulatory changes in the Marketplace.
Key Financial Metrics
| Metric ($ in millions) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenues | $53,579 | $48,742 | $103,523 | $95,362 |
| Premium & Service Revenues | $44,375 | $42,467 | $89,030 | $84,956 |
| Net Earnings (GAAP) | $1,091 | $(253) | $2,632 | $1,058 |
| Adjusted Net Earnings | $1,248 | $(79) | $2,920 | $1,366 |
| Diluted EPS (GAAP) | $2.19 | $(0.51) | $5.30 | $2.13 |
| Diluted EPS (Adjusted) | $2.51 | $(0.16) | $5.88 | $2.75 |
| Operating Cash Flow (6M) | $7,956 (vs. $3,295 in 6M 2025) | |||
| Health Benefits Ratio (HBR) | 89.6% | 93.0% | 88.4% (6M) | 90.2% (6M) |
| SG&A Expense Ratio | 7.0% | 7.1% | 7.3% (6M) | 7.5% (6M) |
| Total Debt | $16,105 | $17,401 | (Current: $75M; Long-term: $16,030M) | |
| Cash & Equivalents | $24,151 | $17,888 | (As of Dec 31, 2025) |
Material Changes vs. Prior Period
- Profitability Surge: The company returned to significant profitability, with Q2 2026 GAAP net earnings of $1.09 billion compared to a loss of $253 million in Q2 2025. This turnaround was driven by improved medical cost management, favorable risk adjustment resolutions, and the absence of the $55 million impairment charge recorded in Q2 2025.
- Revenue Growth: Total revenues increased 10% year-over-year in Q2, primarily due to a 47% increase in premium tax revenue (driven by state pass-through payments) and growth in Medicare PDP premiums. Premium and service revenues grew 4%.
- Membership Decline: Total membership decreased by 8% year-over-year. Medicaid membership declined due to post-pandemic eligibility redeterminations, while Commercial (Marketplace) membership dropped due to the expiration of Enhanced Advance Premium Tax Credits (APTCs) and new regulatory restrictions.
- Debt Reduction: The company aggressively reduced debt, repurchasing $1.3 billion of senior notes during the first six months of 2026. Total debt decreased from $17.4 billion to $16.1 billion.
- Segment Performance:
- Medicaid: Revenues up 14%; Gross margin up 24% due to rate increases and cost management.
- Medicare: Revenues up 17%; Gross margin up 35%, aided by favorable 2025 benefit year resolutions and no premium deficiency reserve in 2026.
- Commercial: Revenues down 7% due to membership loss, but Gross Margin surged 106% to $1.9 billion, driven by pricing actions and risk adjustment transfers.
Guidance, Outlook, and Risks
- Enterprise Optimization: On July 27, 2026, the company announced a voluntary separation program. It estimates recording severance costs of $315 million to $365 million for the remainder of 2026. Total enterprise optimization costs for the first six months were $61 million.
- Regulatory Environment:
- Medicaid: The "One Big Beautiful Bill Act" (OBBBA) passed in July 2025 introduces work requirements and cost-sharing that may increase morbidity and reduce federal funding starting in 2027. California is transitioning 250,000 Medi-Cal members to fee-for-service in 2027.
- Marketplace: Expiration of enhanced subsidies and new integrity rules have reduced membership and increased morbidity. The company has implemented corrective pricing for 95% of its Marketplace membership.
- Medicare: The Inflation Reduction Act (IRA) changes to Part D are stabilizing, with the company noting no premium deficiency reserve for the 2026 contract year.
- Liquidity: The company maintains a strong liquidity position with $24.2 billion in cash and equivalents. It has $1.8 billion remaining under its stock repurchase program and $981 million under its senior note debt repurchase program.
- Legal Proceedings: The company is defending against a federal securities class action and related derivative lawsuits filed in 2025 and 2026 alleging false statements regarding 2025 earnings guidance. Management believes the outcome will not have a material adverse effect, though uncertainties remain.
Investor Verification Checklist
- Membership Trends: Verify the sustainability of the 8% membership decline and the impact of state-specific eligibility redeterminations on future revenue.
- Medical Cost Trends: Assess the durability of the improved Health Benefits Ratio (89.6%) amidst industry-wide inflation and high-cost pharmaceutical releases.
- Regulatory Impact: Monitor the implementation timeline and financial impact of the OBBBA work requirements and the California Medi-Cal transition in 2027.
- Enterprise Optimization Costs: Track the actual execution of the $315M-$365M severance program announced in July 2026 and its impact on future SG&A ratios.
- Debt Repurchase Strategy: Evaluate the remaining capacity ($981M) and terms of the senior note repurchase program and its effect on interest expense.
- Legal Exposure: Review developments in the pending securities class action and derivative lawsuits regarding 2025 earnings guidance.